中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes

文献类型：期刊论文

作者Wu, Ya-li1,2; Xue, Ya-ru1; Guo, Zi-tao1; Chen, Zhen-dong1; Ge, Xin-yu1; Zhong, Da-fang1,2; Diao, Xing-xing1,2
刊名ACTA PHARMACOLOGICA SINICA
出版日期2021-05-25
页码10
关键词furmonertinib (alflutinib AST2818) quantitative proteomics sandwich-cultured human hepatocytes
ISSN号1671-4083
DOI10.1038/s41401-021-00692-7
通讯作者Zhong, Da-fang(dfzhong@simm.ac.cn) ; Diao, Xing-xing(xxdiao@simm.ac.cn)
英文摘要Furmonertinib (Alflutinib, AST2818), as a third-generation epidermal growth factor receptor inhibitor with an advanced efficacy and a relatively wide safety window, has been commercially launched in China recently. However, previous clinical studies demonstrated its time- and dose-dependent clearance in a multiple-dose regimen. In vitro drug metabolism and pharmacokinetic studies have suggested that furmonertinib is mainly metabolized by cytochrome P450 3A4 (CYP3A4) and can induce these enzymes via an increased mRNA expression. This study investigated two important evaluation criteria of CYP3A4 induction by furmonertinib through quantitative proteomics and probe metabolite formation: simultaneous (1) protein expression and (2) enzyme activity with sandwich-cultured primary human hepatocytes in the same well of cell culture plates. Results confirmed that furmonertinib was a potent CYP3A4 inducer comparable with rifampin and could be used as a positive model drug in in vitro studies to evaluate the induction potential of other drug candidates in preclinical studies. In addition, inconsistencies were observed between the protein expression and enzyme activities of CYP3A4 in cells induced by rifampin but not in groups treated with furmonertinib. As such, furmonertinib could be an ideal positive control in the evaluation of CYP3A4 induction. The cells treated with 10 mu M rifampin expressed 20.16 +/- 5.78 pmol/mg total protein, whereas the cells induced with 0.5 mu M furmonertinib expressed 4.8 +/- 0.66 pmol/mg protein compared with the vehicle (0.1% dimethyl sulfoxide), which contained 0.65 +/- 0.45 pmol/mg protein. The fold change in the CYP3A4 enzyme activity in the cells treated with rifampin was 5.22 +/- 1.13, which was similar to that of 0.5 mu M furmonertinib (3.79 +/- 0.52).
WOS关键词TANDEM MASS-SPECTROMETRY ; INTERINDIVIDUAL VARIABILITY ; METABOLIZING-ENZYMES ; HEPATIC EXPRESSION ; LC-MS/MS ; QUANTIFICATION ; RAT ; PROTEIN ; PROTEOMICS ; ISOFORMS
资助项目National Natural Science Foundation of China[81903701]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000654149400002
出版者NATURE PUBLISHING GROUP
源URL[http://119.78.100.183/handle/2S10ELR8/297386]  
专题新药研究国家重点实验室
通讯作者Zhong, Da-fang; Diao, Xing-xing
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201210, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
推荐引用方式
GB/T 7714		 Wu, Ya-li,Xue, Ya-ru,Guo, Zi-tao,et al. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes[J]. ACTA PHARMACOLOGICA SINICA,2021:10.
APA Wu, Ya-li.,Xue, Ya-ru.,Guo, Zi-tao.,Chen, Zhen-dong.,Ge, Xin-yu.,...&Diao, Xing-xing.(2021).Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.ACTA PHARMACOLOGICA SINICA,10.
MLA Wu, Ya-li,et al."Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes".ACTA PHARMACOLOGICA SINICA (2021):10.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。